Gossamer Bio, Inc. (GOSS)
8.77
-0.12
(-1.35%)
USD |
NASDAQ |
Oct 16, 16:00
8.77
0.00 (0.00%)
After-Hours: 20:00
Gossamer Bio Research and Development Expense (Annual) : 174.07M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 174.07M |
| December 31, 2024 | 137.65M |
| December 31, 2023 | 133.70M |
| December 31, 2022 | 169.09M |
| December 31, 2021 | 166.84M |
| Date | Value |
|---|---|
| December 31, 2020 | 158.00M |
| December 31, 2019 | 143.40M |
| December 31, 2018 | 55.28M |
| December 31, 2017 | 0.891M |
| December 31, 2016 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| United Therapeutics Corp. | 550.00M |
| Arbutus Biopharma Corp. | 25.24M |
| Kura Oncology, Inc. | 251.07M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |